Polymer therapeutics as nanomedicines: new perspectives

A growing number of polymer therapeutics have entered routine clinical use as nano-sized medicines. Early products were developed as anticancer agents, but treatments for a range of diseases and different routes of administration have followed – recently the PEGylated-anti-TNF Fab Cimzia® for rheumatoid arthritis and the PEG-aptamer Macugen® for age related macular degeneration. New polymer therapeutic concepts continue to emerge with a growing number of conjugates entering clinical development, for example PEGylated-aptamers and a polymer-based siRNA delivery system. ‘Hot’ topics of the past 2 years include; emerging issues relating to polymer safety, the increasing use of biodegradable polymers, design of technologies for combination therapy, potential biomarkers for patient individualisation of treatment and Regulatory challenges for ‘follow-on/generic’ polymer therapeutics.

► New polymer therapeutics entering clinical use include Cimzia®, Macugen® and Puricase®. ► Novel technologies emerging for combination therapy. ► Polymer therapeutic biomarkers will enable patient individualisation of treatment.